Literature DB >> 24466381

Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.

Xiao-Feng Li1, Tao Huang2, Huijie Jiang3, Xuemei Wang4, Baozhong Shen5, Xiangcheng Wang4, Chin K Ng1, Gregory C Postel1, A Cahid Civelek1.   

Abstract

PURPOSE: The objective is to validate the combination of 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) and (18)F-fluorodeoxyglucose ((18)F-FDG) as a "novel" positron emission tomography (PET) tracer for better visualization of cancer cell components in solid cancers than individual radiopharmaceutical.
METHODS: Nude mice with subcutaneous xenografts of human non-small cell lung cancer A549 and HTB177 cells and patients with lung cancer were included. In ex vivo study, intratumoral radioactivity of (18)F-FDG, (18)F-FLT, and the cocktail of (18)F-FDG and (18)F-FLT detected by autoradiography was compared with hypoxia (by pimonidazole) and proliferation (by bromodeoxyuridine) in tumor section. In in vivo study, first, (18)F-FDG PET and (18)F-FLT PET were conducted in the same subjects (mice and patients) 10 to 14 hours apart. Second, PET scan was also performed 1 hour after one tracer injection; subsequently, the other was administered and followed the second PET scan in the mouse. Finally, (18)F-FDG and (18)F-FLT cocktail PET scan was also performed in the mouse.
RESULTS: When injected individually, (18)F-FDG highly accumulated in hypoxic zones and high (18)F-FLT in proliferative cancer cells. In case of cocktail injection, high radioactivity correlated with hypoxic regions and highly proliferative and normoxic regions. PET detected that intratumoral distribution of (18)F-FDG and (18)F-FLT was generally mismatched in both rodents and patients. Combination of (18)F-FLT and (18)F-FDG appeared to map more cancer tissue than single-tracer PET.
CONCLUSIONS: Combination of (18)F-FDG and (18)F-FLT PET imaging would give a more accurate representation of total viable tumor tissue than either tracer alone and would be a powerful imaging strategy for cancer management.

Entities:  

Year:  2013        PMID: 24466381      PMCID: PMC3890713          DOI: 10.1593/tlo.13577

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  33 in total

1.  Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

Authors:  Sarah R Mudd; Kimberley D Holich; Martin J Voorbach; Todd B Cole; David R Reuter; Paul Tapang; Gail Bukofzer; Arunava Chakravartty; Cherrie K Donawho; Joann P Palma; Gerard B Fox; Mark Day; Yanping Luo
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

2.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Jinming Yu; Xiaorong Sun; Dianbin Mu; Anqin Han
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

3.  Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.

Authors:  Virginie Frings; Adrianus J de Langen; Egbert F Smit; Floris H P van Velden; Otto S Hoekstra; Harm van Tinteren; Ronald Boellaard
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

4.  Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Authors:  Gang Cheng; Thomas C Kwee; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-22       Impact factor: 9.236

5.  High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.

Authors:  Xiao-Feng Li; Yuanyuan Ma; Xiaorong Sun; John L Humm; C Clifton Ling; Joseph A O'Donoghue
Journal:  J Nucl Med       Date:  2010-04       Impact factor: 10.057

6.  Single-scan dual-tracer FLT+FDG PET tumor characterization.

Authors:  Dan J Kadrmas; Thomas C Rust; John M Hoffman
Journal:  Phys Med Biol       Date:  2013-01-08       Impact factor: 3.609

7.  Hypoxia-Induced increase in FDG uptake in MCF7 cells.

Authors:  P Burgman; J A Odonoghue; J L Humm; C C Ling
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

8.  Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia.

Authors:  A C Clavo; R S Brown; R L Wahl
Journal:  J Nucl Med       Date:  1995-09       Impact factor: 10.057

9.  Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy.

Authors:  Xiao-Feng Li; Sean Carlin; Muneyasu Urano; James Russell; C Clifton Ling; Joseph A O'Donoghue
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

Review 10.  FDG uptake, a surrogate of tumour hypoxia?

Authors:  Rudi Andre Dierckx; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-29       Impact factor: 9.236

View more
  6 in total

Review 1.  Systematic imaging in medicine: a comprehensive review.

Authors:  Kai Zhang; Yujie Sun; Shuang Wu; Min Zhou; Xiaohui Zhang; Rui Zhou; Tingting Zhang; Yuanxue Gao; Ting Chen; Yao Chen; Xin Yao; Yasuyoshi Watanabe; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-19       Impact factor: 9.236

2.  Comparison of the diagnostic performance of 18F-fluorothymidine versus 18F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis.

Authors:  Xiao-Feng Li; Dong Dai; Xiu-Yu Song; Jian-Jing Liu; Yan-Jia Zhu; Wen-Gui Xu
Journal:  Mol Clin Oncol       Date:  2014-10-09

Review 3.  Transpathology: molecular imaging-based pathology.

Authors:  Mei Tian; Xuexin He; Chentao Jin; Xiao He; Shuang Wu; Rui Zhou; Xiaohui Zhang; Kai Zhang; Weizhong Gu; Jing Wang; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-13       Impact factor: 9.236

4.  Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'-deoxy-3'-[18F] fluorothymidine in patients with lung cancer.

Authors:  Xiangcheng Wang; Yulin He; Weina Zhou; Xia Bai; Yiwei Wu; Xuemei Wang; Xiao-Feng Li
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

5.  Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.

Authors:  Baozhong Shen; Tao Huang; Yingying Sun; Zhongnan Jin; Xiao-Feng Li
Journal:  Oncotarget       Date:  2017-06-27

6.  (18)F-fluorodeoxyglucose uptake and tumor hypoxia: revisit (18)f-fluorodeoxyglucose in oncology application.

Authors:  Xiao-Feng Li; Yang Du; Yuanyuan Ma; Gregory C Postel; A Cahid Civelek
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.